Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients - PubMed (original) (raw)
Comparative Study
. 2010 Feb 1;126(3):656-68.
doi: 10.1002/ijc.24768.
Affiliations
- PMID: 19626586
- DOI: 10.1002/ijc.24768
Comparative Study
Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients
Barbara Banelli et al. Int J Cancer. 2010.
Abstract
The aim of our study was to identify threshold levels of DNA methylation predictive of the outcome to better define the risk group of stage 4 neuroblastic tumor patients. Quantitative pyrosequencing analysis was applied to a training set of 50 stage 4, high risk patients and to a validation cohort of 72 consecutive patients. Stage 4 patients at lower risk and ganglioneuroma patients were included as control groups. Predictive thresholds of methylation were identified by ROC curve analysis. The prognostic end points of the study were the overall and progression-free survival at 60 months. Data were analyzed with the Cox proportional hazard model. In a multivariate model the methylation threshold identified for the SFN gene (14.3.3sigma) distinguished the patients presenting favorable outcome from those with progressing disease, independently from all known predictors (Training set: Overall Survival HR 8.53, p = 0.001; Validation set: HR 4.07, p = 0.008). The level of methylation in the tumors of high-risk patients surviving more than 60 months was comparable to that of tumors derived from lower risk patients and to that of benign ganglioneuroma. Methylation above the threshold level was associated with reduced SFN expression in comparison with samples below the threshold. Quantitative methylation is a promising tool to predict survival in neuroblastic tumor patients. Our results lead to the hypothesis that a subset of patients considered at high risk-but displaying low levels of methylation-could be assigned at a lower risk group.
Similar articles
- TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC. Shimada H, et al. Cancer. 2004 Oct 15;101(8):1873-81. doi: 10.1002/cncr.20557. Cancer. 2004. PMID: 15386308 - Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. Goto S, et al. Cancer. 2001 Nov 15;92(10):2699-708. doi: 10.1002/1097-0142(20011115)92:10<2699::aid-cncr1624>3.0.co;2-a. Cancer. 2001. PMID: 11745206 - Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
Veschi V, Petroni M, Bartolazzi A, Altavista P, Dominici C, Capalbo C, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A, Giannini G. Veschi V, et al. Cell Death Dis. 2014 Mar 6;5(3):e1100. doi: 10.1038/cddis.2014.68. Cell Death Dis. 2014. PMID: 24603328 Free PMC article. - Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation.
Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Lonergan GJ, et al. Radiographics. 2002 Jul-Aug;22(4):911-34. doi: 10.1148/radiographics.22.4.g02jl15911. Radiographics. 2002. PMID: 12110723 Review. - Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.
Shimada H, Ikegaki N. Shimada H, et al. Biomolecules. 2022 Jan 5;12(1):79. doi: 10.3390/biom12010079. Biomolecules. 2022. PMID: 35053227 Free PMC article. Review.
Cited by
- High-throughput sequencing-based analysis of gene expression of hepatitis B virus infection-associated human hepatocellular carcinoma.
Zeng H, Hui Y, Qin W, Chen P, Huang L, Zhong W, Lin L, Lv H, Qin X. Zeng H, et al. Oncol Lett. 2020 Oct;20(4):18. doi: 10.3892/ol.2020.11879. Epub 2020 Jul 16. Oncol Lett. 2020. PMID: 32774491 Free PMC article. - Discriminating Origin Tissues of Tumor Cell Lines by Methylation Signatures and Dys-Methylated Rules.
Zhang S, Zeng T, Hu B, Zhang YH, Feng K, Chen L, Niu Z, Li J, Huang T, Cai YD. Zhang S, et al. Front Bioeng Biotechnol. 2020 May 26;8:507. doi: 10.3389/fbioe.2020.00507. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32528944 Free PMC article. - Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma.
Maugeri M, Barbagallo D, Barbagallo C, Banelli B, Di Mauro S, Purrello F, Magro G, Ragusa M, Di Pietro C, Romani M, Purrello M. Maugeri M, et al. Oncotarget. 2016 Dec 13;7(50):83330-83341. doi: 10.18632/oncotarget.13090. Oncotarget. 2016. PMID: 27829219 Free PMC article. - The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, Florio T, Daga A, Romani M. Banelli B, et al. Cell Cycle. 2015;14(21):3418-29. doi: 10.1080/15384101.2015.1090063. Cell Cycle. 2015. PMID: 26566863 Free PMC article. - A Pyrosequencing Assay for the Quantitative Methylation Analysis of GALR1 in Endometrial Samples: Preliminary Results.
Kottaridi C, Koureas N, Margari N, Terzakis E, Bilirakis E, Pappas A, Chrelias C, Spathis A, Aga E, Pouliakis A, Panayiotides I, Karakitsos P. Kottaridi C, et al. Biomed Res Int. 2015;2015:756359. doi: 10.1155/2015/756359. Epub 2015 Oct 4. Biomed Res Int. 2015. PMID: 26504828 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous